PEGylation technology and key applications are introduced by this topical volume. Basic physical and chemical properties of PEG as basis for altering/improving in vivo behaviour of PEG-conjugates such as increased stability, improved PK/PD, and decreased immunogenicity, are discussed. Furthermore, chemical and enzymatic strategies for the coupling and the conjugate characterization are reported. Following chapters describe approved and marketed PEG-proteins and PEG-oligonucleotides as well as conjugates in various stages of clinical development.
Inhaltsverzeichnis
Preface PEGylated protein conjugates: A new class of therapeutics for the 21st century. - Protein PEGylation, basic science and biological applications. - Reactive PEGs for protein conjugation. - Rebridging disulphides: site-specific PEGylation by sequential bis-alkylation. - Enzymatic techniques for PEGylation of biopharmaceuticals. - The site-specific TGase-mediated PEGylation of proteins occurs at flexible sites. - Protein conjugates purification and characterization. - PEG and PEG conjugates toxicity: towards an understanding of the toxicity of PEG and its relevance to PEGylated biologicals. - The occurrence, induction, specificity and potential effect of antibodies against poly(ethylene glycol). - Pegfilgrastim designing an improved form of rmetHuG-CSF. - PEGylation of human growth hormone: strategies and properties. - PEGylated ? interferons: two different strategies to achieve increased efficacy. - Development of PEGylated mammalian urate oxidase as a therapy for patients with refractory gout. - Certolizumab pegol: a PEGylated anti-tumour necrosis factor alpha biological agent. - PEG: a useful technology in anticancer therapy. - Regulatory strategy and approval processes considered for PEG-drug conjugates and other nanomedicines.